Lipid Armor Loaded with Doxylamine and Gemfibrozil for Glioblastoma Therapy: Particle Engineering and Multidimensional Two-Dimensional/Three-Dimensional Antitumor Efficacy Authors: Smita Dey, Sakshi Priya, Gautam Singhvi, Rajdeep Chowdhury, Shibasish Chowdhury Published: 2025 ABSTRACT Glioblastoma multiforme (GBM) is an aggressive and highly treatment-resistant brain tumor with a poor prognosis and limited therapeutic options. Temozolomide (TMZ), the current standard chemotherapeutic agent, often fails due to acquired resistance and its high systemic toxicity at therapeutic doses. In our recent study, we repurposed two FDA-approved drugs, Doxylamine and Gemfibrozil, as potential alternatives to TMZ for GBM treatment. Both agents demonstrated superior efficacy in vitro, with lower IC50 values (∼750 μM for Doxylamine and ∼300 μM for Gemfibrozil) compared to TMZ (∼1.25 mM). However, at these concentrations, the free drugs still exhibited off-target toxicity to noncancerous cells. To address this, in this study, we developed solid lipid nanoparticle (SLN) formulations of Doxylamine and Gemfibrozil to prevent off-target distribution and enhance their therapeutic index. Compared to the free drugs, the SLN formulations reduced IC50 values (1.5 to 1.66-fold) in GBM cells, indicating enhanced potency. Furthermore, nanoencapsulation enhanced cellular uptake, minimized cytotoxic effects on healthy cells, and enabled effective drug action at significantly lower concentrations. Mechanistic studies carried out in 2D and 3D cultures of U87 cells revealed that both free and nanoformulation-encapsulated drugs inhibited autophagy flux and triggered apoptotic pathways in GBM cells, with the nanoformulations exhibiting greater selectivity and efficiency. These results underscore the advantages of SLN-based Doxylamine and Gemfibrozil delivery over their free forms, highlighting their promise as safer and more effective treatment options for GBM. Introduction Glioblastoma multiforme (GBM) is the most aggressive and lethal form of primary brain tumor in adults, accounting for nearly 50% of all malignant brain tumors. It is characterized by rapid and infiltrative growth, extensive intratumoral heterogeneity, resistance to standard therapies, and a strong tendency for recurrence. GBM cells aggressively invade the surrounding brain tissue, making complete surgical resection virtually impossible without damaging vital neurological functions. Even after maximal surgical removal followed by concurrent chemoradiotherapy, recurrence is almost inevitable, typically within 6–9 months. − The tumor’s resistance to treatment is multifactorial, driven by the presence of glioblastoma stem-like cells, robust DNA repair mechanisms, altered cell death pathways, and limited drug penetration across the blood–brain barrier (BBB). − These factors contribute to the dismal prognosis, with a median survival of only 12–15 months and a 5-year survival rate of less than 5%, despite aggressive multimodal treatment. The high fatality rate, rapid progression, and poor quality of life underscore the urgent and unmet need for the development of more effective and less toxic therapeutic strategies. Currently, Temozolomide (TMZ) is the standard first-line chemotherapeutic agent approved by the FDA for the treatment of GBM. Although TMZ exhibits initial clinical benefits, its effectiveness is significantly limited due to intrinsic or acquired resistance, particularly mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). , Moreover, TMZ demonstrates a relatively high IC50 (∼1.25 mM), necessitating elevated doses that contribute to substantial toxicity in normal brain tissue and peripheral organs. These limitations underscore the necessity for alternative therapeutic agents with improved efficacy and safety profiles. In our recent studies, we explored Doxylamine (DOX), an H1-antihistamine, and Gemfibrozil (GEM), a lipoprotein lipase inhibitor or peroxisome proliferator-activated receptor (PPAR) agonist, both of which have shown potential antitumor effects through mechanisms such as autophagic flux inhibition, endoplasmic reticulum (ER)-stress induced apoptosis, and disruption of calcium homeostasis. In vitro studies revealed lower IC50 values for DOX (∼600 μM) and GEM (∼250 μM) compared to TMZ, suggesting their potential as more effective alternatives for GBM treatment. However, like TMZ, these drugs also pose a risk of off-target toxicity at therapeutically relevant concentrations. To address these challenges and improve the therapeutic index, as a follow-up to our existing study, we developed nanoparticle-based drug delivery systems. These systems are known to enhance the delivery of therapeutic agents to tumor sites while minimizing systemic side effects. Specifically, in GBM, nanoparticle formulations help circumvent critical barriers such as poor BBB permeability, rapid drug degradation, and nonspecific distribution. For example, liposomes, polymeric nanoparticles, and lipid-based nanocarriers have been successfully employed to deliver drugs like paclitaxel, doxorubicin, and curcumin with enhanced efficacy and reduced toxicity. Among these platforms, solid liquid nanoparticle (SLNs) offer several unique advantages, including biocompatibility, the ability to incorporate both hydrophilic and lipophilic drugs, physical stability, controlled release, and potential for surface modification to improve BBB penetration. Their relatively simple manufacturing process and scalability also make SLNs an attractive option for clinical translation. , In this study, we aimed to formulate and characterize DOX- or GEM-loaded SLNs to overcome the limitations associated with free drug administration. These nanoformulations were designed to enhance drug delivery to GBM cells, minimize cytotoxic effects on healthy tissues, and improve the therapeutic efficacy at lower concentrations. Our findings reveal that SLN-based formulations of DOX and GEM led to a reduction in the IC50 values compared to their free drug counterparts, indicating enhanced potency. This effect was consistently observed in both conventional 2D monolayer cultures and more physiologically relevant 3D spheroid models of glioblastoma. Additionally, these SLNs were found to inhibit autophagic flux, thereby triggering apoptosis similar to the effects observed with the free drugs, further validating the therapeutic potential of the formulations. Overall, the results highlight the potential of SLNs as a promising drug delivery platform that can enhance the safety and effectiveness of repurposed drugs for glioblastoma treatment. Materials and Methodology Materials Precirol ATO 5 (glyceryl palmitostearate) and Kolliphor CS12 were generously provided as free sample gifts from Gattefosse, India, and Lubrizol (Belgium), respectively. For the in vitro part of the study, the U87 and LN229 cells were procured from the National Centre for Cell Science (NCCS), Pune. Annexin V and Mitotracker DeepRed were procured from Invitrogen. In addition, Protease Inhibitor Cocktail (PIC, no. P8340), Radio-Immunoprecipitation Assay (RIPA) Buffer (no. R0278), and Propidium Iodide (PI, no. P4864) were also obtained from Sigma. The drugs Doxylamine (#D3775) and Gemfibrozil (#69518) were procured from Sigma-Aldrich. Temozolomide (#85622–93–1) and Coumarin-6 were purchased from TCI Chemicals. From Thermo Fisher Scientific, we procured 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (#33,611; MTT was obtained from SRL. Annexin V binding buffer (#V13246), FITC conjugated Annexin V (#A13199), Enhanced Chemiluminescence (ECL, #32106), Lipofectamine-3000 (#L3000–001), Antifademountant (4′-6-diamidino-2-phenylindole, #P36962) were purchased from Invitrogen. Anti-Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) (#sc-365062) was procured from Santa Cruz Biotechnology. Primary antibodies, such as anti-p62 (#D1Q5S), anti-LC3B–II (#D-11 3868S), anti-PCNA (#D3H8P), and anti-Caspase-3 (#D3R6Y 14220), as well as secondary antibodies antirabbit (#7074P2) and antimouse (#7076S), were procured from Cell Signaling Technology (CST). Chlorpromazine (#SC-357313) and Dynasore (#SC-202592) were procured from Santa Cruz. Nocodazole (#M1404) was procured from Sigma-Aldrich, and Genistein (#G0272) was procured from TCI. Methyl cellulose (#GRM7262) was procured from Himedia. Development and Optimization of Solid Lipid Nanoparticle Formulations The selection of lipids and surfactants was based on the current literature, primary trials, and previous laboratory experience. The solid lipid (150 mg) was placed in a vial and melted in a water bath at a temperature of 65 ± 5 °C. The drug (10 mg) was added to the melted lipid mixture. The specified surfactant solution (0.55%) was prepared in deionized water in another glass vial and maintained at a temperature of 65 ± 5 °C. Then, the surfactant solution was added slowly to the melted solid lipid mixture with constant stirring at 400–500 rpm. The dispersion was then maintained under hot stirring at the same temperature conditions for 45 to 60 min. Afterward, probe sonication of the prepared dispersion was carried out under hot conditions for a duration of 5 min maintained on a 30 on 10 s off cycle with 20% amplitude. The vial was then immediately cooled in an ice bath for a duration of 30 to 45 min with constant stirring at 300 to 400 rpm. The entire process of preparation of SLNs is the same for both DOX and GEM drugs (DOX-SLNs and GEM-SLNs). All experimentation was carried out under dark conditions since both the drugs are sensitive to light and degrade in its presence. Characterization of Developed Solid Lipid Nanoparticle Formulations Size, Polydispersity Index, and Zeta Potential Analysis The three main formulation parameters examined were particle size, polydispersity index (PDI), and zeta potential, determined using dynamic light scattering with a Zetasizer (Malvern Zetasizer Nano 3600, UK). The DOX-SLNs and GEM-SLNs were first centrifuged at 8000 rpm at 4 °C for 5 min, and then the supernatant was diluted prior to analyzing the particle size, PDI, and zeta potential. Three duplicates of each measurement were made at 25 °C, with at least 15 and 50 runs for particle size and zeta potential analysis, respectively. Entrapment Efficiency and Assay Analysis The centrifugation method was used to determine the % entrapment efficiency (EE). The known volume of the developed DOX-SLNs and GEM-SLNs formulations was centrifuged for 5 min at 8000 rpm at 4 °C. The supernatant was collected from the first centrifuge cycle and then centrifuged again for 30 min at 17,000 rpm at 4 °C. The supernatant was collected and examined using Spectra Manager software on a Jasco V-750 UV–visible Spectrophotometer. The amount of drug entrapped was estimated by using the in-house analytical method developed by using a UV–visible Spectrophotometer. The % EE was calculated using the equation mentioned below. entrapmentefficiency=amountofdrugentrappedtotalamountofdrugpresent×100 The total amount of DOX and GEM present in the DOX-SLNs and GEM-SLNs was determined by facilitating the lysis of the developed nanoparticles using methanol. The mixture was then centrifuged for 20 min at 15,000 rpm at 4 °C. The supernatant was collected and analyzed using a UV–visible Spectrophotometer. Morphological Characterization of DOX-SLN and GEM-SLN Dispersion Field-emission scanning electron microscopy (FESEM) was used to characterize the morphologies of the optimized DOX-SLNs and GEM-SLNs. To investigate the surface topography of the developed formulations, dispersion FESEM [Apreo Switch XT instrument) was employed. The dispersion was applied to the coverslip and then vacuum-dried. Samples were prepared on double-sided tape and covered with a thin coating of gold using a sputter coater unit (Quorum Q150 T ES, Quorum Technologies Ltd., UK) prior to morphological property evaluation. Solid-State Characterization The developed formulations were lyophilized with 5% mannitol as a cryoprotectant using a Labconco Freezone for solid-state characterization. The lyophilized samples were used in attenuated total reflection infrared spectroscopy (ATR-IR), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC). To verify the encapsulation of DOX and GEM in the prepared SLNs and assess the compatibility between the drugs and the excipients used, ATR-IR spectra were obtained by scanning from 4000 to 400 cm–1. The spectra of the pure Dox, physical mixture (a simple blend of the DOX and SLNs excipients without any formulation processing), and lyophilized DOX-SLNs, individually and similarly pure GEM, physical mixture (a simple blend of the GEM and SLNs excipients without any formulation processing), and lyophilized GEM-SLNs, were recorded at a resolution of 1 cm–1 using ATR spectroscopy equipment (Bruker, USA). − A PXRD (Rigaku, Miniflex) was used to analyze the X-ray diffraction patterns for the pure DOX, physical mixture, and lyophilized DOX-SLNs, and similarly, pure GEM, physical mixture, and lyophilized GEM-SLNs in order to determine the crystallinity. PXRD tests were conducted in the scanning range of 3 to 40° angles in the case of DOX-SLNs and 3 to 70° with a step size of 0.01°, accelerating voltage of 40 kV, beam current of 40 mA, and data collection duration of 1.0 s/step. DSC analysis was performed on the pure DOX, physical mixture, and lyophilized DOX-SLNs, and similarly, pure GEM, physical mixture, and lyophilized GEM-SLNs using the DSC-60 (Shimadzu, Japan) equipment. The sample (5 mg) was placed in an aluminum pan with a lid and sealed with a crimper. This was placed in the sample holder. The formulations and the drug’s pure thermograms were compared. The gas flow rate was 30 mL/min, and the heating rate was 10 °C/min. The study was conducted at temperatures ranging from 25 to 150 °C. − Hemolysis Study Fresh blood was drawn from Wistar rats into 10% w/v EDTA (ethylenediamine tetraacetic acid-coated Eppendorf tubes). The red blood cell (RBCs) pellet was obtained by centrifuging the tubes for 5 min at 4 °C and 1000 rpm. After being washed with 0.9% normal saline, the resulting RBC pellet was centrifuged again for 5 min at 1000 rpm. A 20x dilution of normal saline was used to resuspend the resulting pellet. The purpose of the study was to assess the hemolytic capabilities of pure Dox, DOX-SLNs, pure Gem, and GEM-SLNs. In 1 mL Eppendorf tubes, 100 μL of the RBC suspension was mixed with 100 μL (0.1% of DOX and 0.1% of GEM in respective DOX-loaded SLNs and GEM-loaded SLNs) of each formulation. In place of formulation, 1% Triton X and normal saline were added to the RBC solution for the positive and negative controls, respectively. The Eppendorf tubes were incubated for 30 min at 37 °C. After incubation, the sample was diluted with normal saline and centrifuged again at 1000 rpm for 5 min at 4 °C to settle the intact RBCs. Using the BioTek Epoch Microplate reader (Gen5 3.10 software), the absorbance of the supernatant was measured at 540 nm. , The % hemolysis was calculated using the equation mentioned below: hemolysis(%)=sampleabsorbance−negativecontrolabsorbancepositivecontrolabsorbance−negativecontrolabsorbance×100 Additionally, the microscopic images of each sample were captured using a Zeiss microscope. In Vitro Drug Release Study An in vitro drug release study was conducted to investigate the release pattern of DOX and GEM from their free solution form and SLN formulations using a Franz diffusion cell apparatus and dialysis membrane technique in phosphate-buffered saline (PBS), pH 7.4. An equivalent concentration (0.1%) of DOX and GEM was taken in the donor compartment from their free solution forms and developed SLN formulations, respectively. PBS was placed in the receptor compartment. The entire setup was maintained at 37 ± 0.5 °C with constant stirring at 150 rpm. The samples were taken at intervals of 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 h and replenished with the same dissolving media to maintain the sink condition. The collected samples were analyzed using an in-house developed method for DOX and GEM in PBS, utilizing a UV–visible Spectrophotometer at 260 nm (DOX λmax) and 274 nm (GEM λmax). After analyzing the findings, the graph was displayed with time (at which 100% release was achieved) on the x-axis and the percentage of cumulative drug release on the y-axis. DD Solver, an Excel add-in, was used to assess the drug release mechanism. Internalization of the Nanoparticles in 2D and 3D Models Coumarin-6-loaded nanocarriers were assessed for their internalization potential using both U87 monolayer cells and U87 spheroid models. The fluorescent dye Coumarin-6 was encapsulated within solid lipid nanoparticles (SLNs) to enable the visualization of nanoparticle uptake and trafficking pathways. This green fluorescent tagging facilitated the tracking of SLN localization and helped determine its homing behavior within the cellular and spheroid environments. The cells were incubated with the nanocarriers for 3 h, while the spheroid cultures were incubated for 24 h to assess the effective uptake. To determine the intracellular localization of the nanocarriers, mitochondria were stained with Mitotracker, highlighting potential mitochondrial targeting. The cells were subsequently fixed using 2% paraformaldehyde (PFA) and permeabilized with 0.1% Triton X for enhanced imaging clarity. Antifade 4’,6-diamidino-2-phenylindole (DAPI) was used to mount the samples, ensuring clear nuclear visualization. The internalization and distribution of the nanocarriers were then analyzed under a ZEISS Apotome fluorescence microscope for both 2D cells and 3D spheroid cultures. The 3D spheroids were generated by using the procedure outlined in a subsequent section. The fold change in nanoparticle internalization was calculated using ImageJ software by measuring the green fluorescence intensity, which directly correlates with the number of nanoparticles taken up by the cells. All of the experiments were repeated three times, unless mentioned otherwise. Evaluation of Pathways of Endocytosis through Flow Cytometry Six × 105 U87 cells (6 × 105) were seeded and treated with various endocytosis inhibitors, including chlorpromazine (CPZ), genistein (Gen), nocodazole (Noc), and dynasore (Dyn). Post-treatment with inhibitors, the cells were subjected to treatment with Coumarin-6 loaded formulations of DOX and GEM and incubated for 48 h. The cells were trypsinized and analyzed through flow cytometry (Beckman Coulter) to understand the pathway of interaction of the nanoparticles with the glioblastoma cells, and were analyzed using CytExpert 3.0. , The fold change in the amount of internalization of the nanoparticles was calculated by using Graphpad Prism 8. All the experiments were repeated thrice, until and unless mentioned otherwise. MTT Assay Cytotoxicity analysis of selected FDA-approved drugs (Doxylamine and Gemfibrozil) and drug-loaded nanoparticles (DOX-SLNs and GEM-SLNs) was performed on glioblastoma cell lines U87 and LN229 (obtained from NCCS, Pune, India) over 48 h by using standard protocols. The effects of these drug-loaded formulations were compared with the free drugs. Briefly, cells were seeded at a density of 1 × 106 cells per well in a 96-well plate and treated with SLNs or free drugs and post incubation, MTT was added, and live cells were allowed to form formazan crystals, and the amount of formazan formed is proportional to cell viability, measured by absorbance at 570 nm using a Microplate reader. , All the experiments were repeated thrice, until and unless mentioned otherwise. Cell Viability Study by Annexin V For this study, cells were seeded in 6 cm dishes at a 6 × 105 cells per dish cell density. To determine the total number of dead cells, U87 and LN229 cells are stained with Annexin V and PI. Briefly, IC50 values of the drug-loaded nanoparticles (DOX-SLNs and GEM-SLNs) treatment were given to the cultured cells and incubated for 48 h at 37 °C. The IC50 dosage of the DOX-SLNs was 450 μM, and that of Gem-SLNs was 200 μM. The treatment was then followed by flow cytometric analysis (Beckman Coulter) of apoptosis using Annexin V–PI. The CytExpert software was used for acquired data analysis. All the experiments were repeated thrice, until and unless mentioned otherwise. 3D Spheroid Culture The cells were first trypsinized and then suspended in a single-cell solution. To enhance the viscosity of the suspension and facilitate spheroid formation via the hanging drop method, methylcellulose was added, and 10,000 cells per 10 μL were maintained to form a sphere. Ten μL of the cell mixture was then added dropwise to the lid of the 10 cm Petri plate and kept in an inverted position, and 10 mL of phosphate-buffered saline was added to the plate to provide moisture to the cells. The spheroids were allowed to take their shape; thereafter, the spheroids were transferred to a round-bottomed 96-well plate, and the drug-loaded SLNs were added. At regular intervals, phase contrast images were captured to determine the change in the shape of the spheroids. Additionally, spheroids stained with PI were used to accurately count the number of dead cells trapped inside and to measure fluorescence intensity under Microscopy (Zen 3.2 Blue edition). After 5 days of treatment with the SLNs, the protein was extracted from the spheroids, and Immunoblotting was performed to determine the expression of different proteins. Immunoblotting 2D and 3D spheroids of the U87 cells treated with drugs were harvested in RIPA buffer, followed by protein estimation using the Bradford assay. An equal amount of protein loaded in polyacrylamide gels was transferred to the poly­(vinylidene fluoride) (PVDF) membrane, followed by blocking with skimmed milk. The probing and reprobing of blots were performed using primary antibodies (dilution 1:1000), and detection was carried out on a ChemiDoc (Bio-Rad) system using Enhanced Chemiluminescence (ECL). As loading control, GAPDH and total Histone (dilution 1:2000) were used. When necessary, blots were cut to probe with various antibodies to determine protein expression of distinct molecular weights. , All the experiments were repeated thrice, until and unless mentioned otherwise. Statistical Data Analysis All experimental data are presented as mean ± standard deviation (SD). Statistical comparisons between two groups were performed using unpaired t tests, while one-way and two-way ANOVA were applied for multiple group comparisons under identical or varying experimental conditions. Analyses were conducted using GraphPad Prism 8. Bonferroni correction was applied for multiple comparisons. A p-value <0.05 was considered statistically significant. Significance levels are indicated as follows: *p ≤ 0.03, **p ≤ 0.002, and ***p < 0.00019. All the experiments were repeated thrice, until and unless mentioned otherwise. Results Development and Optimization of Solid Lipid Nanoparticle Formulations Among a range of solid lipids, such as Compritol 888 ATO, stearic acid, precirol ATO 5, and others, precirol ATO 5 was selected based on the highest solubility of DOX and GEM in it (among all, only 75 mg of precirol ATO 5 was sufficient to dissolve 5 mg of each drug), emulsification effectiveness, and stability of the developed nanoparticle. Second, among various surfactants, including sodium lauryl sulfate, Kolliphor CS12, Tween 80, and poloxamer 407, Kolliphor CS12 was selected after observing the smaller particle size, optimum PDI, and highest EE obtained from the developed SLNs. Therefore, the optimized composition resulted in the formation of stable Dox-loaded SLNs and Gem-loaded SLNs, which were further characterized for the estimation of the drugs using the developed in-house analytical method (Figure S1A,B). Characterization of Developed Solid Lipid Nanoparticle Formulations Size, Polydispersity Index, and Zeta Potential Analysis The particle sizes of the developed DOX-SLNs and GEM-SLNs were found to be 123.5 ± 3.64 and 115.2 ± 8.28 nm, respectively. The PDI of the developed DOX-SLNs and GEM-SLNs was found to be 0.217 ± 0.02 and 0.082 ± 0.01, respectively (as shown in Figure A,B). The zeta potential of the developed DOX-SLNs and GEM-SLNs was found to be −26.4 ± 0.004 and −28.4 ± 0.008 mV, respectively (as shown in Figure C,D). (A, B) Particle size report of (A) Dox-loaded SLNs and (B) Gem-loaded SLNs. (C, D) Zeta potential report of (C) Dox-loaded SLNs and (D) Gem-loaded SLNs. Entrapment Efficiency and Assay Analysis The optimized batch of DOX-SLNs and GEM-SLNs exhibited an EE (%) of 76.88 ± 2.94% and 78.63 ± 1.95%, respectively. Furthermore, the drug assay results (%) were found to be 98.78 ± 2.71% and 99.02 ± 0.78% for DOX-SLNs and GEM-SLNs, respectively. The findings demonstrated that both drugs have strong lipophilicity and excellent solubility in the lipid matrix. Morphological Characterization of DOX-SLN and GEM-SLN Dispersion The morphological characterization of the developed DOX-SLNs and GEM-SLNs was performed using FESEM, as shown in Figure A,B, respectively. The FESEM images showed that both the developed particles had a spherical shape with a uniform and smooth surface. Additionally, the particle size observed using FESEM was similar to that obtained using the Malvern Zetasizer. FESEM images of (A) Dox-loaded SLNs and (B) Gem-loaded SLNs. Solid-State Characterization ATR study gives details on a compound’s physical state, molecular interactions, and chemical structure, as shown in Figure A,B. The prominent peaks of the DOX were observed at 1200–1350 cm–1 (C–N Stretch), 1050–1150 cm–1 (C–O Stretch), 1450–1600 cm–1 (CC Stretch), and 700–900 cm–1 (Benzene Ring Substitution Peaks) and the peaks present in the GEM were observed at 1700–1720 cm–1 (CO Stretch), 1200–1320 cm–1 (C–O stretch), 1450–1600 cm–1 (CC Stretch), 1350–1470 cm–1 (C–H Bending), and 910–950 cm–1 (O–H Bending). , The spectrum of the developed DOX-SLNs and GEM-SLNs showed some peaks of DOX and GEM, respectively, which might be because of the presence of the drug in the surfactant layer. Furthermore, the peaks observed in the case of drug-loaded SLNs were similar to those of the blank SLNs without peaks of drugs (Figure S2A,B), indicating that the observed peaks were due to the excipients used to prepare the SLNs. The results obtained can be further confirmed by PXRD and DSC studies. (A, B) ATR spectrum of (A) pure DOX, physical mixture, and DOX-loaded SLNs and (B) pure GEM, physical mixture, and GEM-loaded SLNs. (C, D) Powder X-ray diffractogram of (C) pure DOX, physical mixture, and DOX-loaded SLNs and (D) pure GEM, physical mixture, and GEM-loaded SLNs. (E, F) Differential scanning calorimetry of (E) pure DOX, physical mixture, and DOX-loaded SLNs and (F) pure GEM, physical mixture, and GEM-loaded SLNs. To ascertain the physicochemical state of the encapsulated drug and confirm that it was dispersed in microcrystalline form without passing through polymorphic or transitional modifications to an amorphous state, powder XRD was utilized. Figure C,D depicts the diffractograms of the pure DOX, physical mixture, and lyophilized DOX-SLNs individually and similarly pure GEM, physical mixture, and lyophilized GEM-SLNs. The diffractogram of the developed DOX-SLN and GEM-SLN formulation showed decreased characteristic diffraction peaks of pure DOX and GEM, which might be due to the encapsulation of DOX and GEM in the SLNs or the solubility of DOX and GEM in the lipid solution. ,, Furthermore, the diffractogram of the blank SLNs (Figure S2C,D) does not exhibit any peaks of the drugs, like in drug-loaded SLNs, which clearly indicates that the observed peaks were due to the excipients used to prepare the SLNs, and these peaks were not present in the drug’s diffractogram. DSC analyzes the physical state and thermal properties to determine the effects of interactions between the drug and the excipient. The DSC thermograms of DOX and GEM (Figure E,F) showed an endothermic melting peak at 110.67 and 63.05 °C, respectively, indicating the crystallinity of DOX and GEM. In the case of the respective developed formulations, there was an absence of the endothermic peak of DOX and GEM, which may be due to the entrapment of DOX and GEM in the developed SLNs. Furthermore, the thermogram of the blank SLNs (Figure S2E,F) does not exhibit any peaks corresponding to the drugs, indicating that the observed peaks were due to the excipients used in the SLN preparation. Hemolysis Study When given into the bloodstream, nanoparticles are likely to interact with the components of the blood. To assess the hemolytic toxicity of the developed nanoparticles, hemolysis characterization was performed. As seen in Figure A,B, respectively, the microscopic pictures and the Eppendorf tubes clearly demonstrate full hemolysis in the positive control group and no hemolysis in the negative control and both formulation-treated groups. Additionally, the % hemolysis obtained quantitatively was also less than 1% in both of the developed formulations. Hemolysis results (A) Microscopic images of hemolysis study of different groups (Scale bar represents 10 μM) and (B) Eppendorf images showing hemolysis results of different groups. In Vitro Drug Release Study The release of DOX from the free-DOX solution and DOX-SLNs and the free GEM solution and GEM-SLNs over the dialysis membrane is illustrated in Figure A,B. The calibration curves for both drugs in PBS (pH 7.4) are shown in Figure S3. The DOX and GEM were completely released (100%) from the free-DOX solution and the free-GEM solution within 30 min and 1 h, respectively. Furthermore, burst release was observed in the cases of DOX-SLNs (51%) and GEM-SLNs (34%) within 30 min and showed sustained release up to 6 h in the case of DOX-SLNs and 12 h in the case of GEM-SLNs. Furthermore, the drugs were also observed to be stable at physiological pH for the duration of the study (24 h). Table displays the potential release kinetics information, correlation coefficients (R 2), Akaike information criterion (AIC), and model selection criteria (MSC) values for the free-DOX solution and DOX-SLNs, as well as the free-GEM solution and GEM-SLNs. The best-fit kinetic model was selected based on those with the highest correlation coefficient, the lowest AIC, and the highest MSC values. The DOX and GEM were found to follow the first-order kinetic model from their free solution, as indicated by the highest R 2: 0.829, AIC: 37.230, and MSC: 1.434 values in the case of the free-DOX solution and R 2: 0.965, AIC: 17.981, and MSC: 3.067 values in the case of the free-GEM solution. Furthermore, both developed SLNs (DOX-SLNs and GEM-SLNs) followed the Korsmeyer–Peppas model, as indicated by the highest R 2 values of 0.962 in the case of DOX-SLNs and 0.962 in the case of GEM-SLNs, along with the lowest AIC and MSC values of 25.531 and 2.475 for DOX-SLNs, and 37.549 and 2.715 for GEM-SLNs, respectively. The DOX and GEM were found to follow a Fickian diffusion (case I transport) mechanism, as indicated by the n values of 0.305 and 0.357 from DOX-SLNs and GEM-SLNs, respectively. In vitro release profile of (A) free doxylamine and doxylamine-loaded SLNs and (B) free gemfibrozil and gemfibrozil-loaded SLNs. 1Summarized Table Depicting the Best-Fit Release Kinetic Models for Free-DOX Solution, DOX-SLNs, and Free-GEM Solution and GEM-SLN Dispersions free-DOX solutionDOX-SLNsfree-GEM solutionGEM-SLNskinetics model R 2 AICMSC R 2 AICMSC R 2 AICMSC R 2 AICMSC zero order –8.66461.447–2.601–1.19843.849–1.187–86.95072.791–4.762–0.11359.298–0.392 first order 0.82937.2301.4340.71433.6510.8510.96517.9813.0670.65251.1590.770 Hixson–Crowell –2.52255.391–1.5920.56935.6980.442–35.90166.711–3.8940.53153.2480.471 Higuchi –2.85255.929–1.6820.67734.2490.732–36.11466.751–3.8990.86744.3801.738 Korsmeyer–Peppas 0.41446.626–0.1310.96225.5312.475NANANA0.96237.5492.715T50 (h) = 0.181; T80 (h) = 0.420 n = 0.305; T50 (h) = 0.587; T80 (h) = 2.737T50 (h) = 0.196; T80 (h) = 0.454 n = 0.357; T50 (h) = 2.016; T80 (h) = 7.508 Summarized Table Depicting the Best-Fit Release Kinetic Models for Free-DOX Solution, DOX-SLNs, and Free-GEM Solution and GEM-SLN Dispersions Further, the t 50 and t 80 values were 3.25-fold and 6.5-fold higher in the case of DOX-SLNs compared with the free-DOX solution, respectively. Similarly, 10.28-fold and 16.54-fold higher t 50 and t 80 values in the case of GEM-SLNs were observed compared to the free-GEM solution, respectively. The obtained findings thereby indicate the sustained-release nature of the developed formulation. Internalization of the Nanoparticles After the successful development of formulation and characterization of DOX-SLNs and GEM-SLNs, studies were conducted to assess their localization within cancer cells. This step is crucial for understanding the cellular targeting and internalization properties of the nanoparticles. To achieve this, the nanoparticles were tagged with coumarin-6, a fluorescent dye, to facilitate visualization via fluorescence microscopy. For investigations, U87 glioblastoma cells were used as a model system. These cells were trypsinized, seeded onto coverslips, and allowed to grow to the required confluency. Following this, the cells were treated with coumarin-6 labeled nanoparticles and incubated at 37 °C for 24 h to enable sufficient interaction and uptake. To visualize mitochondrial alignment, the mitochondria of the cells were tagged using Mitotracker, a specific dye for mitochondrial labeling. Fluorescence imaging was performed to analyze the localization of the nanoparticles within the cells. The images clearly demonstrated that the nanoparticles had successfully entered the U87 cells. Additionally, the fluorescence indicated that the nanoparticles were predominantly present in the cytoplasm, with partial colocalization with mitochondria, confirming their intracellular uptake and specific alignment within key cellular structures (Figure A). Determining the cellular uptake of the nanoparticles in (A) 2D (scale bar represents 10 μM) and (B) 3D cultures (scale bar represents 100 μM): Uptake of nanoparticles in U87 cells and evaluation of internalization rates in 3D spheroid GBM cultures were studied using coumarin-6 loaded nanoparticles. Post-treatment, yellow puncta observed in U87 cells confirmed nanoparticle internalization, aligning with the mitochondria. Additionally, increased green fluorescence in the spheroid cultures post-treatment further validated the internalization of the formulations. Statistical comparisons between two groups were performed using unpaired t tests, while one-way and two-way ANOVA were applied for multiple group comparisons under identical or varying experimental conditions. Analyses were conducted using GraphPad Prism 8. Bonferroni correction was applied for multiple comparisons. A p-value of <0.05 was considered statistically significant. Significance levels are indicated as follows: *p ≤ 0.03, **p ≤ 0.002, and ***p < 0.00019. To further validate these findings and assess the behavior of the nanoparticles in a more physiologically relevant model, the coumarin-6-labeled nanoparticles were subjected to a 3D spheroid culture of U87 cells. Spheroid cultures mimic the three-dimensional structure and microenvironment of tumors, providing more accurate insights into the penetration and localization of therapeutic agents. After the spheroids were treated with the coumarin-6-tagged nanoparticles and incubated for 48 h, fluorescence imaging was performed. The results revealed a strong green fluorescence signal within the spheroids compared to the control samples, confirming that the nanoparticles effectively penetrated the 3D tumor-like structure and localized within the U87 cells (Figure B). Analysis of the bar plot revealed that green fluorescence intensity and thus nanoparticle internalization were approximately 10–15 times higher in spheroid cultures compared to the control, indicating markedly enhanced uptake in the 3D cellular model. The DIC images of the spheroid cultures are also provided which shows the formation and the structure of the spheroids (Figure S4). Establishing the Route of Internalization of Nanoformulations To understand the route of internalization of the nanoparticles, the cells were pretreated with different inhibitors of endocytosis. Multiple endocytic pathways, including phagocytosis, macropinocytosis, and clathrin- and caveolae-independent endocytosis (CCIE), have been implicated in the internalization of nanoparticles. To investigate the roles of these pathways, specific inhibitors were used: CPZ to block clathrin-mediated endocytosis (CME), Gen to inhibit caveolae-mediated endocytosis (CVE), Noc to disrupt actin-driven macropinocytosis, and Dyn to inhibit dynamin-dependent processes. To account for the possibility that blocking one pathway could activate compensatory uptake via alternative endocytic routes, internalization studies were performed after 1 h of nanoparticle exposure to capture the immediate effect of pathway inhibition. Flow cytometry revealed that actin-driven macropinocytosis was not involved, as nocodazole (Noc) treatment had no effect on uptake. In contrast, significant reductions were observed with genistein (Gen) and dynasore (Dyn), indicating that nanoparticles predominantly enter cells via caveolae- and dynamin-dependent pathways. Gen pretreatment led to an approximately 10-fold decrease in uptake, while Dyn caused a 5-fold reduction. Chlorpromazine (CPZ), a clathrin-mediated endocytosis (CME) inhibitor, produced only a mild effect, suggesting that CME plays a minimal role in nanoparticle entry. Overall, these results indicate that caveolae- and dynamin-mediated endocytosis are the primary mechanisms of nanoparticle internalization (Figure ). Investigation of the internalization pathway of coumarin-6-loaded nanoparticles in U87 cells using endocytosis inhibitors: The internalization route of nanoparticles in U87 cells was investigated using various endocytosis inhibitors. Flow cytometric analysis revealed that the nanoparticles primarily utilize caveolae-mediated and dynamin-mediated endocytosis, while inhibiting macropinocytosis and clathrin-mediated endocytosis showed no impact on nanoparticle uptake. Here, the following abbreviations were used: D = dynasore; G = genistein; C = chlorpromazine; N = nocodazole. Significance levels are indicated as follows: *p ≤ 0.03, **p ≤ 0.002, and ***p < 0.00019. Cytotoxicity Effect of the Nanoparticles After confirmation of the ability of the nanoparticles to penetrate cancer cells, the next step was to evaluate their cytotoxic effects on U87 glioblastoma cells. This was assessed using an MTT assay. U87 cells were seeded in a 96-well plate at a density of 8 × 104 cells per well and allowed to adhere and attain their morphology. The cells were then treated with DOX-SLNs and GEM-SLNs individually and incubated for 48 h and compared with free DOX and GEM, respectively. Following the treatment period, MTT dye was added to each well, allowing viable cells to form formazan crystals, and the resulting fluorescence intensity was measured to quantify the cytotoxicity. The analysis revealed that cells treated with DOX-SLNs and GEM-SLNs exhibited significant cytotoxic effects after 48 h, comparable to the cytotoxicity observed in cells treated with the free drugs. This indicates that the SLNs effectively deliver the drug payloads. The IC50 values for the nanoparticle formulations ranged between 200 and 500 μM, closely matching the previously reported IC50 values of the corresponding free drugs. Specifically, the Dox-SLNs exhibited an IC50 of approximately 500 μM, while the GEM-SLNs demonstrated a lower IC50 of around 200 μM, indicating an enhanced potency. Notably, the SLNs displayed even greater efficacy than the free drug alone, with a p value of <0.03, confirming the improved therapeutic performance of the SLN formulations in GBM cells (Figure A). Further, Annexin V–PI staining was conducted on U87 and LN229 glioblastoma cells treated with DOX-SLNs and GEM-SLNs to evaluate cell death. Fold changes in the proportion of dead cells were calculated relative to those of the untreated controls. The results showed a marked increase in cytotoxicity in nanoparticle-treated cells, confirming the effectiveness of the drug-loaded SLN formulations against glioblastoma (Figure B). LN229 cells exhibited greater sensitivity, with a 6–7-fold increase in total cell death, while U87 cells showed a 3–4-fold increase, demonstrating that the drugs retained their cytotoxic potential against GBM cell lines even after encapsulation. Evaluation of the cytotoxic effects of drug-loaded nanoparticles compared to free drugs in U87 cells after 48 h of treatment: (A) To evaluate the cytotoxic effects of the nanoformulations, an MTT assay was conducted at varying doses and compared with free drugs. The results showed that Dox-loaded SLNs had an IC50 value of approximately 450 μM, while Gem-loaded SLNs demonstrated a lower IC50 value of around 200 μM, indicating superior efficiency compared to the free drugs (IC50 value of free DOX is around 750 μM and that of Gem is around 300 μM) and (B) annexin V–PI assay confirmed the total number of dead cells post-treatment in both U87 and LN229 cell lines, validating the MTT results. Significance levels are indicated as follows: *p ≤ 0.03, **p ≤ 0.002, and ***p < 0.00019. Effect of the Nanoparticles on 3D Spheroids Following the evaluation of DOX-SLNs and GEM-SLNs on Glioma cells, their effectiveness was further validated in U87 spheroid cultures. Treatments were administered and assessed using PI staining, a method that selectively labels dead cells at 1, 3, and 7 days post-treatment. The elevated PI uptake in nanoparticle-treated spheroids directly reflected drug-induced cell death. PI is a membrane-impermeable dye that penetrates only cells with compromised plasma membranes, characteristic of late apoptosis or necrosis. Once internalized, it binds to nucleic acids, emitting a strong red fluorescence. Fluorescence imaging showed a marked increase in red fluorescence intensity in spheroids treated with the nanoparticles, particularly after 3 days, confirming their cytotoxic effects. Additionally, phase contrast imaging was performed on days 1 and 7 of treatment to observe changes in the spheroid shape and size. A significant reduction in spheroid size was observed by day 7, further demonstrating the efficacy of the formulations (Figure A,B). (A) Assessment of cytotoxic effects of formulations on 3D spheroid cultures using PI staining and measurement of spheroid size reduction post-treatment via phase contrast imaging: The impact of the nanoformulations was assessed in 3D spheroid cultures of Glioblastoma cells. An increase in red fluorescence intensity over time post-treatment indicated a time-dependent rise in the toxic effects of the nanoparticles on GBM cells (scale bar represents 100 μM). (B) Additionally, phase contrast imaging revealed a reduction in spheroid size following treatment, further demonstrating the formulations’ effectiveness in targeting the cells. Scale bar represents 20 μM. Significance levels are indicated as follows: *p ≤ 0.03, **p ≤ 0.002, and ***p < 0.00019. Estimating the Protein Expression Postnanoparticle Treatment To investigate alterations in protein expression following treatment with drug-loaded nanoparticles, U87 glioblastoma cells were seeded and allowed to reach confluency before treatment. After exposure to DOX-SLNs and GEM-SLNs, proteins were isolated and analyzed by using immunoblotting. The results showed a reduction in the expression of proliferating cell nuclear antigen (PCNA), a marker of cell proliferation, comparable to treatment with the free drugs. Additionally, the levels of cleaved caspase-3, an apoptotic marker, were significantly increased with both SLNs. In parallel, 3D spheroid cultures were also treated with the SLNs and compared with untreated controls. Similar trends were observed, with increased cleaved caspase-3 levels and decreased PCNA expression. Furthermore, elevated levels of p62 and LC3B, markers associated with autophagy, were found. The observed effects were consistent in both 2D and 3D glioblastoma models and were comparable to the results obtained with free drug treatments, confirming the efficacy of the drug-loaded nanoparticles (Figure A–C). Quantification of protein levels of PCNA and cleaved caspase-3 post-treatment in the U87 cells, along with p62 and LC3b levels, to assess autophagic pathway inhibition: Western blot analysis revealed a significant reduction in the expression of the proliferation marker PCNA in GBM cells treated with (A) DOX-loaded and (B) GEM-loaded SLNs, as well as free drugs, compared to untreated cells. Enhanced levels of the apoptotic marker, cleaved caspase-3, further confirmed the efficacy of the formulations, and (C) similar results were observed in 3D spheroid cultures of U87 cells. Additionally, increased expression of autophagy markers p62 and LC3B indicated the inhibition of autophagic flux post-treatment, leading to heightened cellular stress, disrupted homeostasis, and increased cell death in Glioblastoma cells. A p value <0.05 was considered statistically significant. Significance levels are indicated as follows: *p ≤ 0.03, **p ≤ 0.002, and ***p < 0.00019. Discussion Glioblastoma remains one of the most challenging malignancies to treat owing to its invasive nature, poor response to conventional therapies, and limited drug penetration across the BBB. While repurposed agents like DOX and GEM have demonstrated promising cytotoxic potential against GBM cells, their clinical applicability is hindered by relatively high IC50 values and associated off-target toxicity. Therefore, in this study, we have overcome this limitation by developing SLN-based delivery systems for both drugs. Both of the developed SLNs showed optimum particle size, PDI, and zeta potential, which are within the optimal range for intravenous (IV) drug delivery. Nanoparticles smaller than 200 nm are preferred for systemic circulation as they can evade rapid clearance by the reticuloendothelial system (RES) and enhance passive accumulation at tumor sites through the enhanced permeability and retention (EPR) effect. The optimum PDI minimizes aggregation risks and ensures consistent circulation and biodistribution profiles. The obtained zeta potential indicates good colloidal stability resulting from electrostatic repulsion between particles, which prevents aggregation under physiological conditions. A negative surface charge is often beneficial for IV administration, as it reduces opsonization and uptake by macrophages, prolonging systemic circulation. This charge may be endorsed due to the composition of lipids and surfactants used, which can also influence cellular uptake and interaction with glioblastoma cells. , Furthermore, when we evaluated the EE of the developed SLNs, we found a high EE. In SLNs, strong drug–lipid interactions improve drug retention. Increased % EE may result from van der Waals forces or hydrophobic contacts formed by the drug’s and lipid’s functional groups. The morphology of the developed SLNs was observed, demonstrating a symmetric spherical shape that facilitates a simpler membrane wrapping during endocytosis. Their higher surface-area-to-volume ratio results in longer-lasting drug release and higher drug loading. This improves intracellular delivery and cell membrane contact. Then, we checked the drug excipient compatibility by performing solid-state characterizations, and all of the ATR-IR, PXRD, and DSC findings suggested the successful entrapment of the drug inside the developed SLNs and no interference between the drug and the excipients utilized to develop SLNs. Furthermore, the outcome of the hemolysis study suggested that the drugs, as well as the excipients used to develop the formulations, are safe for intravenous administration, as they do not damage blood cells, thereby further supporting their biocompatibility for in vivo applications. , After confirmation of the biocompatibility properties of the developed formulation, the in vitro drug release behavior was assessed in order to comprehend the release kinetics and mechanism controlling drug diffusion from the carrier system. The rapid release of both drugs in their free drug solution form demonstrates their immediate solubilization and diffusion into the release medium. On the other hand, the developed SLN formulation exhibited an initial burst release due to the free drug in the developed SLNs and the drugs available in the surfactant layer. It then showed sustained release, indicating the encapsulation of the drugs within the lipid matrix, which led to a slower diffusion of drug molecules through the solid lipid phase. Furthermore, the obtained findings were supported by kinetic model fitting, which showed that the free drug followed a first-order release kinetic model, demonstrating the dependency of drug release on the remaining concentration of the drug in solution. On the other hand, both developed formulations followed the Korsmeyer–Peppas release kinetics model, with n values less than 0.4, indicating that the initial release of the drug is controlled by diffusion through the lipid matrix, later by matrix erosion. Moreover, the higher t 5 0 and t 8 0 values for both developed SLNs further demonstrate the therapeutic benefits of the SLN system. Such a sustained-release profile may be beneficial for preserving therapeutic medication levels over an extended period, reducing the need for frequent dosing, and perhaps enhancing patient compliance. After the successful development of formulation and characterization of DOX-SLNs and GEM-SLNs, studies were conducted to assess their localization within cancer cells. The findings of the study collectively indicate that the coumarin-6-tagged Dox-SLNs and GEM-SLNs not only possess the ability to enter glioblastoma cells but also demonstrate targeted alignment with critical organelles such as the mitochondria. Moreover, their successful penetration into 3D spheroid models highlights their potential for effective tumor targeting and delivery in more complex biological systems. Furthermore, the IC50 values of the drug-loaded SLNs were comparable to those of the free drug, indicating that the excipients in the formulation are safe and do not compromise the drug’s therapeutic activity. Following the evaluation of DOX-SLNs and GEM-SLNs on U87 and LN229 cells, their efficacy was further validated in U87 spheroid models. These findings confirm that both DOX-SLNs and GEM-SLNs effectively target glioblastoma cells in 2D and 3D culture systems. The effective concentration range of Gemfibrozil was approximately 92–273 μM, , while that of Doxylamine was around 380 μM in noncancerous cells after 72 h of treatment. Hence, the IC50 values determined in this study fall well within the established safety margins of these drugs after exposure for 48 h of exposure. Alterations in protein expression following treatment with drug-loaded nanoparticles were also evaluated on U87 glioblastoma cells. The results showed a reduction in the expression of proliferating cell nuclear antigen (PCNA), a marker of cell proliferation, comparable to that of untreated controls. Additionally, the levels of cleaved caspase-3, an apoptotic marker, were significantly increased with both SLNs, indicating the activation of apoptotic pathways. In parallel, 3D spheroid cultures were also treated with the SLNs and compared to untreated controls. Similar trends were observed with increased cleaved caspase-3 levels and decreased PCNA expression, confirming that the formulations induced apoptosis and inhibited proliferation in the spheroids. Furthermore, elevated levels of p62 and LC3B, markers associated with autophagy, suggested that the nanoparticles effectively blocked the autophagic pathway. This disruption of autophagy likely contributed to increased cellular stress, disruption of homeostasis, and ultimately cell death. Overall, by significantly lowering the IC50 values and enhancing drug selectivity, these SLNs offer a promising strategy to overcome the limitations of both TMZ and the free forms of DOX and GEM. Conclusions In this study, we successfully addressed the high IC50 values and associated off-target toxicity limitations by formulating SLN-based delivery systems for both drugs, aiming to enhance therapeutic efficacy while reducing systemic toxicity. Comprehensive physicochemical characterization confirmed the successful synthesis and stability of the nanocarriers, while biological assays demonstrated improved cellular uptake, enhanced cytotoxicity against GBM cells, and reduced toxicity in noncancerous environments. The particle size and zeta potential analyses confirmed the size and structural integrity of the nanoparticles. ATR-IR spectroscopy was employed to assess potential interactions between the drugs and polymers, while XRD and DSC analyses provided evidence of the successful encapsulation of the drugs within the nanocarriers. SEM imaging further confirmed the spherical shape and consistent size of the nanoparticles. The hemolysis assay demonstrated the safety profile of the formulations, collectively verifying that both nanocarriers were synthesized with comparable integrity. The internalization process and the uptake mechanisms of the developed nanoparticles were investigated using various endocytosis inhibitors, confirming that the nanoparticles predominantly utilized caveolae-mediated and dynamin-mediated pathways for cellular entry. Once internalized, both nanocarriers exhibited cytotoxic effects, as validated through the MTT and Annexin V/PI assays. Protein expression analysis revealed a decrease in PCNA levels and an increase in cleaved caspase-3 expression in cells treated with the nanocarriers compared to those treated with free drugs, further confirming the efficacy and functionality of the nanocarriers. Additionally, the modulation of autophagy was evident from the accumulation of p62 and LC3B, indicating the impact of the nanocarriers on the autophagic pathways. Importantly, the developed SLNs showed consistent and superior performance in both 2D and 3D culture models, highlighting their translational relevance. Overall, this work lays a strong foundation for the further preclinical development of nanoformulated repurposed drugs as safer, more effective alternatives for glioblastoma therapy, potentially transforming current treatment paradigms. Supplementary Material